To determine whether circulatory levels of IL9 or IL18 in PDA patients differ from healthy individuals and whether they potentially reflect systemic tumor responses, we compared IL9 and IL18 blood levels of our patient cohort with an age-matched control group of healthy individuals (n=30). This evidence concerns the gene IL9 and Patent ductus arteriosus.